ZA200109006B - Aromatic sulfone hydroxamic acid metalloprotease inhibitor. - Google Patents

Aromatic sulfone hydroxamic acid metalloprotease inhibitor. Download PDF

Info

Publication number: ZA200109006B
Authority: ZA; South Africa
Prior art keywords: alkyl; group; aryl; alkoxy; cycloalkyl
Prior art date: 1999-05-14

Application number

ZA200109006A

Other languages

English (en)

Inventor

Thomas E Barta

Daniel P Becker

Louis J Bedell

Terri L Boehm

Jeffery N Carroll

Gary A De Crescenzo

Yvette M Fobian

John N Freskos

Daniel P Getman

Joseph J Mcdonald

Susan L Hockerman

Carol Pearcy Howard

Madeleine Hui Li

Deborah A Mischke

Joseph G Rico

Nathan W Stehle

Michael B Tollefson

William F Vernier

Clara I Villamil

Stephen A Kolodziej

Original Assignee

Searle & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-14

Filing date

2001-10-31

Publication date

2002-12-02

2001-10-31 Application filed by Searle & Co filed Critical Searle & Co

2002-12-02 Publication of ZA200109006B publication Critical patent/ZA200109006B/en

Links

125000003118 aryl group Chemical group 0.000 title claims description 111
150000003457 sulfones Chemical class 0.000 title claims description 30
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title description 14
239000002253 acid Substances 0.000 title description 9
101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 title description 4
239000003475 metalloproteinase inhibitor Substances 0.000 title description 4
-1 hydroxycarbonylcarbonyl Chemical group 0.000 claims description 106
125000001072 heteroaryl group Chemical group 0.000 claims description 91
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 87
150000001875 compounds Chemical class 0.000 claims description 83
125000000753 cycloalkyl group Chemical group 0.000 claims description 73
125000001424 substituent group Chemical group 0.000 claims description 72
229910052799 carbon Inorganic materials 0.000 claims description 67
229910052757 nitrogen Inorganic materials 0.000 claims description 67
229910052739 hydrogen Inorganic materials 0.000 claims description 48
239000001257 hydrogen Substances 0.000 claims description 48
150000003839 salts Chemical class 0.000 claims description 45
125000000217 alkyl group Chemical group 0.000 claims description 43
125000003710 aryl alkyl group Chemical group 0.000 claims description 43
125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 43
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 37
229910052717 sulfur Inorganic materials 0.000 claims description 37
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 31
229910052760 oxygen Inorganic materials 0.000 claims description 27
125000003435 aroyl group Chemical group 0.000 claims description 24
150000003462 sulfoxides Chemical class 0.000 claims description 23
230000000694 effects Effects 0.000 claims description 21
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
102000005741 Metalloproteases Human genes 0.000 claims description 20
108010006035 Metalloproteases Proteins 0.000 claims description 20
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 20
125000003545 alkoxy group Chemical group 0.000 claims description 20
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 20
239000001301 oxygen Substances 0.000 claims description 20
239000011593 sulfur Substances 0.000 claims description 20
125000005842 heteroatom Chemical group 0.000 claims description 19
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 17
125000004104 aryloxy group Chemical group 0.000 claims description 16
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 16
125000003627 8 membered carbocyclic group Chemical group 0.000 claims description 15
125000004429 atom Chemical group 0.000 claims description 15
125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 14
229910020008 S(O) Inorganic materials 0.000 claims description 14
108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 13
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 12
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 11
229920001774 Perfluoroether Chemical group 0.000 claims description 11
125000005843 halogen group Chemical group 0.000 claims description 11
101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 10
102100027995 Collagenase 3 Human genes 0.000 claims description 10
108050005238 Collagenase 3 Proteins 0.000 claims description 10
102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 10
125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 10
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 9
125000001589 carboacyl group Chemical group 0.000 claims description 9
230000002401 inhibitory effect Effects 0.000 claims description 9
230000001575 pathological effect Effects 0.000 claims description 9
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 8
125000001188 haloalkyl group Chemical group 0.000 claims description 8
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
125000003342 alkenyl group Chemical group 0.000 claims description 7
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 7
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 7
230000001747 exhibiting effect Effects 0.000 claims description 7
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 7
125000005553 heteroaryloxy group Chemical group 0.000 claims description 7
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
239000011159 matrix material Substances 0.000 claims description 7
125000004103 aminoalkyl group Chemical group 0.000 claims description 6
125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 6
125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 5
125000005164 aryl thioalkyl group Chemical group 0.000 claims description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
125000005010 perfluoroalkyl group Chemical group 0.000 claims description 5
125000005236 alkanoylamino group Chemical group 0.000 claims description 4
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 4
125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims description 4
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims description 3
125000000623 heterocyclic group Chemical group 0.000 claims description 3
125000002837 carbocyclic group Chemical group 0.000 claims description 2
125000006239 protecting group Chemical group 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 42
125000004356 hydroxy functional group Chemical group O* 0.000 claims 28
125000004446 heteroarylalkyl group Chemical group 0.000 claims 11
239000008194 pharmaceutical composition Substances 0.000 claims 8
125000002102 aryl alkyloxo group Chemical group 0.000 claims 6
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 6
125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 6
125000004950 trifluoroalkyl group Chemical group 0.000 claims 6
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
239000003937 drug carrier Substances 0.000 claims 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
230000005764 inhibitory process Effects 0.000 description 15
108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
102000002274 Matrix Metalloproteinases Human genes 0.000 description 11
108010000684 Matrix Metalloproteinases Proteins 0.000 description 11
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
241000124008 Mammalia Species 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
238000000034 method Methods 0.000 description 8
102000003390 tumor necrosis factor Human genes 0.000 description 8
229940124761 MMP inhibitor Drugs 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
125000001145 hydrido group Chemical group *[H] 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
230000008569 process Effects 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 6
102100040247 Tumor necrosis factor Human genes 0.000 description 6
210000002808 connective tissue Anatomy 0.000 description 6
125000004475 heteroaralkyl group Chemical group 0.000 description 6
OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 6
229950008959 marimastat Drugs 0.000 description 6
102000029816 Collagenase Human genes 0.000 description 5
108060005980 Collagenase Proteins 0.000 description 5
102100030416 Stromelysin-1 Human genes 0.000 description 5
229960002424 collagenase Drugs 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
102100030417 Matrilysin Human genes 0.000 description 4
108090000855 Matrilysin Proteins 0.000 description 4
102000035195 Peptidases Human genes 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 3
102100027998 Macrophage metalloelastase Human genes 0.000 description 3
108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 3
102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
102000056189 Neutrophil collagenases Human genes 0.000 description 3
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
101710108790 Stromelysin-1 Proteins 0.000 description 3
102100028848 Stromelysin-2 Human genes 0.000 description 3
230000009471 action Effects 0.000 description 3
210000002469 basement membrane Anatomy 0.000 description 3
XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 3
229950001858 batimastat Drugs 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
239000000816 peptidomimetic Substances 0.000 description 3
230000008439 repair process Effects 0.000 description 3
230000035939 shock Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
206010028391 Musculoskeletal Pain Diseases 0.000 description 2
206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
108030001564 Neutrophil collagenases Proteins 0.000 description 2
229940124639 Selective inhibitor Drugs 0.000 description 2
102100028847 Stromelysin-3 Human genes 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 2
125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000005129 aryl carbonyl group Chemical group 0.000 description 2
125000005110 aryl thio group Chemical group 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 2
125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
125000001151 peptidyl group Chemical group 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
235000019833 protease Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
108091007196 stromelysin Proteins 0.000 description 2
125000003107 substituted aryl group Chemical group 0.000 description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
208000037259 Amyloid Plaque Diseases 0.000 description 1
102000005862 Angiotensin II Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
206010053555 Arthritis bacterial Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010061619 Deformity Diseases 0.000 description 1
108700034813 EC 3.4.24.17 Proteins 0.000 description 1
108700033382 EC 3.4.24.22 Proteins 0.000 description 1
108700033384 EC 3.4.24.24 Proteins 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000004575 Infectious Arthritis Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
108030001712 Macrophage elastases Proteins 0.000 description 1
101710187853 Macrophage metalloelastase Proteins 0.000 description 1
108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 1
108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
108010013295 Microbial collagenase Proteins 0.000 description 1
101150101095 Mmp12 gene Proteins 0.000 description 1
206010062207 Mycobacterial infection Diseases 0.000 description 1
102100030411 Neutrophil collagenase Human genes 0.000 description 1
101710118230 Neutrophil collagenase Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
229940122055 Serine protease inhibitor Drugs 0.000 description 1
101710102218 Serine protease inhibitor Proteins 0.000 description 1
101710108792 Stromelysin-2 Proteins 0.000 description 1
108050005271 Stromelysin-3 Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
101710151579 Zinc metalloproteinase Proteins 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
230000032683 aging Effects 0.000 description 1
125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000001691 aryl alkyl amino group Chemical group 0.000 description 1
125000004659 aryl alkyl thio group Chemical group 0.000 description 1
125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000008355 cartilage degradation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000470 constituent Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000000000 cycloalkoxy group Chemical group 0.000 description 1
125000005366 cycloalkylthio group Chemical group 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
230000035558 fertility Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
125000005368 heteroarylthio group Chemical group 0.000 description 1
125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
125000004476 heterocycloamino group Chemical group 0.000 description 1
125000004470 heterocyclooxy group Chemical group 0.000 description 1
125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
230000000222 hyperoxic effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
208000027531 mycobacterial infectious disease Diseases 0.000 description 1
239000002547 new drug Substances 0.000 description 1
125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000008458 response to injury Effects 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
201000001223 septic arthritis Diseases 0.000 description 1
239000003001 serine protease inhibitor Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000000464 thioxo group Chemical group S=* 0.000 description 1
230000008427 tissue turnover Effects 0.000 description 1
210000000515 tooth Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

ZA200109006A 1999-05-14 2001-10-31 Aromatic sulfone hydroxamic acid metalloprotease inhibitor. ZA200109006B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US31183799A	1999-05-14	1999-05-14

Publications (1)

Publication Number	Publication Date
ZA200109006B true ZA200109006B (en)	2002-12-02

Family

ID=27757522

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200109006A ZA200109006B (en)	1999-05-14	2001-10-31	Aromatic sulfone hydroxamic acid metalloprotease inhibitor.

Country Status (5)

Country	Link
AR (1)	AR035547A1 (es)
CO (1)	CO5251417A1 (es)
PE (1)	PE20010202A1 (es)
UY (1)	UY26145A1 (es)
ZA (1)	ZA200109006B (es)

2000
- 2000-05-15 UY UY26145A patent/UY26145A1/es not_active Application Discontinuation
- 2000-05-15 PE PE2000000455A patent/PE20010202A1/es not_active Application Discontinuation
- 2000-05-15 AR ARP000102342 patent/AR035547A1/es not_active Application Discontinuation
- 2000-05-15 CO CO00035030A patent/CO5251417A1/es not_active Application Discontinuation
2001
- 2001-10-31 ZA ZA200109006A patent/ZA200109006B/en unknown

Also Published As

Publication number	Publication date
CO5251417A1 (es)	2003-02-28
AR035547A1 (es)	2004-06-16
UY26145A1 (es)	2000-12-29
PE20010202A1 (es)	2001-02-19

Publication	Publication Date	Title
ZA200106492B (en)	2003-05-07	Sulfamato hydroxamide acid metalloprotease inhibitor.
ZA200106780B (en)	2002-08-16	Aromatic sulfone hydroxamic acid metalloprotease inhibitor.
AU723658B2 (en)	2000-08-31	Reversible cysteine protease inhibitors
EP0946166B1 (en)	2004-02-18	Use of matrix metalloproteinase inhibitors for promoting wound healing
KR100400507B1 (ko)	2003-10-08	치환 피롤리딘 히드록사메이트 메탈로프로테아제 억제제
JPS6339855A (ja)	1988-02-20	Ａｃｅ阻害剤の抗高血圧活性を高める医薬組成物
BRPI0612607A2 (pt)	2010-12-07	inibidores de alfa proteìna de ativação de fibroblasto
CA2555457C (en)	2012-08-21	A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als
EP1098651A2 (de)	2001-05-16	Neue urokinase-inhibitoren
ZA200109007B (en)	2003-01-31	Hydroxamic acid derivatives as matrix metalloprotease inhibitors.
JP2008544988A (ja)	2008-12-11	眼細胞におけるゼラチナーゼａ活性を増大するための、カルボニル部分で置換されたアリールアジンを含む製剤
US7071211B2 (en)	2006-07-04	Small organic molecules that increase the activity of gelatinase a in ocular cells
US20040186060A1 (en)	2004-09-23	Matriptase inhibitors and methods of use
ZA200109228B (en)	2002-11-15	$G(A)-amino-$G(B)-sulfonyl hydroxamic acid compounds.
WO2002064552A8 (en)	2002-12-12	1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
ZA200109006B (en)	2002-12-02	Aromatic sulfone hydroxamic acid metalloprotease inhibitor.
ES2277623T3 (es)	2007-07-16	Derivados de amida del acido fenoxi-n-'4-(isotiazolidin-1,1-dioxido-2-il)fenil)-valerianico y otros compuestos como inhibidores del factor de la coagulacion xa para el tratamiento de enfermedades tromboembolicas y de tumores.
WO1997041864A1 (en)	1997-11-13	Ophthalmic preparations
US7342018B2 (en)	2008-03-11	Urokinase inhibitors and uses thereof
EP0509442A1 (en)	1992-10-21	Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
US20030220383A1 (en)	2003-11-27	Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
US7538216B2 (en)	2009-05-26	Guanidino phenylalanin compounds used as urokinase inhibitors
KR20040044514A (ko)	2004-05-28	항혈전약과 피라졸론 유도체의 조합 약제
ES3045582T3 (en)	2025-11-28	Cathepsin inhibitors
EP0166257A2 (en)	1986-01-02	Cardiovascular composition